<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> is widely used for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Although it reduces hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production, clinical studies show that <z:chebi fb="0" ids="6801">metformin</z:chebi> may reduce plasma dipeptidyl peptidase-4 activity and increase circulating levels of glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) </plain></SENT>
<SENT sid="2" pm="."><plain>We examined whether <z:chebi fb="0" ids="6801">metformin</z:chebi> exerts glucoregulatory actions via modulation of the incretin axis </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> action was assessed in Glp1r(-/-), Gipr(-/-), Glp1r:Gipr(-/-), Pparα (also known as Ppara)(-/-) and hyperglycaemic <z:mp ids='MP_0001261'>obese</z:mp> <z:mp ids='MP_0002169'>wild-type</z:mp> mice with or without the GLP-1 receptor (GLP1R) <z:chebi fb="68" ids="48706">antagonist</z:chebi> exendin(9-39) </plain></SENT>
<SENT sid="4" pm="."><plain>Experimental endpoints included <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance, plasma insulin levels, gastric emptying and food intake </plain></SENT>
<SENT sid="5" pm="."><plain>Incretin receptor expression was assessed in isolated islets from <z:chebi fb="0" ids="6801">metformin</z:chebi>-treated <z:mp ids='MP_0002169'>wild-type</z:mp> and Pparα(-/-) mice, and in INS-1 832/3 beta cells with or without peroxisome proliferator-activated receptor (PPAR)-α or <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK) <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In <z:mp ids='MP_0002169'>wild-type</z:mp> mice, <z:chebi fb="0" ids="6801">metformin</z:chebi> acutely increased plasma levels of GLP-1, but not those of gastric inhibitory <z:chebi fb="1" ids="15841">polypeptide</z:chebi> or <z:chebi fb="7" ids="16670">peptide</z:chebi> YY; it also improved oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance and reduced gastric emptying </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> significantly improved oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance despite loss of incretin action in Glp1r(-/-), Gipr(-/-) and Glp1r(-/-) :Gipr(-/-) mice, and in <z:mp ids='MP_0002169'>wild-type</z:mp> mice fed a high-fat diet and treated with exendin(9-39) </plain></SENT>
<SENT sid="8" pm="."><plain>Levels of <z:chebi fb="2" ids="33699">mRNA</z:chebi> transcripts for Glp1r, Gipr and Pparα were significantly increased in islets from <z:chebi fb="0" ids="6801">metformin</z:chebi>-treated mice </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> directly increased Glp1r expression in INS-1 beta cells via a PPAR-α-dependent, AMPK-independent mechanism </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> failed to induce incretin receptor gene expression in islets from Pparα(-/-) mice </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS/INTERPRETATION: As <z:chebi fb="0" ids="6801">metformin</z:chebi> modulates multiple components of the incretin axis, and enhances expression of the Glp1r and related insulinotropic islet receptors through a mechanism requiring PPAR-α, <z:chebi fb="0" ids="6801">metformin</z:chebi> may be mechanistically well suited for combination with incretin-based therapies </plain></SENT>
</text></document>